Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing Somatic EGFR Mutation Testing

摘要: Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with clinical response and prolonged survival patients non-small cell lung cancer (NSCLC) treated EGFR tyrosine kinase inhibitors (TKIs). We began screening for somatic by DNA sequencing as part of care 2004. performed a retrospective cohort study 278 NSCLC referred testing over 10-month period. Tumor samples underwent direct sequence analyses exons 18 through 24. determined characteristics mutation status analyzed their to therapy survival. were identified 68 (24%) patients. A minimal smoking history was strongest predictor harboring mutation. In multivariable analyses, each pack-year corresponded 5% decreased likelihood having an Among 92 unresectable disease undergoing subsequent systemic therapy, increased rate TKIs (p < .0001) but not chemotherapy. Overall significantly mutation-positive = .001), median 3.1 years compared 1.6 mutation-negative patients, after adjusting age, gender, stage at diagnosis. Integrating molecular profiling into is feasible provides useful information.